Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

BRCR Global

Neither a doctor nor a teaching hospital

Research payments

$468,255

220 payments

Through program year 2025, BRCR Global is reported as receiving $468,255 in research payments, across 220 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $267,210 165
2024 Research $48,945 7
2023 Research $2,253 3
2022 Research $30,029 4
2021 Research $119,817 41

Breakdown

Who paid Research payments · program years 2021–2025
  1. Daiichi Sankyo Inc. $147,118 156 payments
  2. Celgene Corporation $145,187 7 payments
  3. Eisai Inc. $125,846 44 payments
  4. Napo Pharmaceuticals Inc $24,000 1 payment
  5. E.R. Squibb & Sons, L.L.C. $19,206 4 payments
  6. Pfizer Inc. $6,550 4 payments
  7. Moderna TX, Inc. $271 3 payments
  8. Epizyme, Inc., $78 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors $125,846 44 payments
  2. A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge $70,164 2 payments
  3. Ds1062-328 $53,222 10 payments
  4. Ds8201-793 $48,436 87 payments
  5. Ds3201-330 $43,974 54 payments
  6. Ph III Iberdomide (EXCALIBER) RRMM (1-2 prior) $36,900 1 payment
  7. A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial $26,323 2 payments
  8. A Phase 3 Multicenter, Randomized, Double Blind Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted-Cancer Therapies with or without Standar Chemotherapy $24,000 1 payment
  9. A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent $13,035 1 payment
  10. A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) $10,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record